Lymphoma Treatment Resolved Severe Blood Disorder
A recent case report highlights how targeted lymphoma therapy helped a patient overcome refractory cold agglutinin disease.
Updated on Sept. 25, 2026 in Cancer
At the SOHO 2026 Annual Meeting held September 9-12, 2026, clinicians described a 73-year-old patient who successfully resolved stage 4 diffuse large B-cell lymphoma and associated severe hemolysis. The findings underscore a potential treatment pathway for patients experiencing unusual hematologic symptoms linked to underlying malignancy.
Why it matters
This case illustrates the importance of identifying underlying cancers in patients presenting with rare, life-threatening blood disorders. By successfully treating the primary lymphoma, clinicians were able to resolve the patient's severe anemia and hemolysis.
A case report of a 73-year-old woman with stage 4 diffuse large B-cell lymphoma and 95% bone marrow involvement detailed the results of 6 cycles of R-pola-CHP therapy. The patient achieved a complete metabolic response and regained transfusion independence.
The players
SOHO
The Society of Hematologic Oncology is a professional organization focused on the exchange of research regarding hematologic malignancies.
The details
The patient initially presented with cold agglutinin disease, a condition where the immune system attacks red blood cells in response to cold temperatures. Because standard interventions failed to stop the rapid destruction of red blood cells, clinicians used the medication sutimlimab to bridge the patient to lymphoma treatment. Once stable, she received 6 cycles of R-pola-CHP, an intensive regimen that directly targets the malignant B-cells responsible for both the tumor and the abnormal antibodies.
Timeline
September 9-12, 2026: The case report was presented at the SOHO 2026 Annual Meeting.
February 2026: The patient was confirmed to be in remission and transfusion-independent.
Health Landscape
This report highlights a shift toward integrating targeted oncology therapies with supportive care for patients with hematologic paraneoplastic syndromes. It adds to the ongoing effort at the SOHO 2026 Annual Meeting to optimize treatment strategies for high-risk B-cell malignancies.
Patients presenting with unexplained, severe anemia or signs of hemolysis should discuss comprehensive hematological testing with their doctor to rule out underlying malignancies. This case demonstrates why addressing the root cause of systemic symptoms is critical for effective long-term care.
The takeaway
This case serves as a reminder that complex blood disorders can sometimes act as early clinical markers for aggressive cancers. If you are managing symptoms of persistent anemia or hemolysis, discuss the necessity of bone marrow and malignancy screenings with your hematologist.
Further reading
For more information on how current research is shaping oncology care, visit our Cancer section.
Source note: This article includes information reported by Oncology Nurse Advisor.
